ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography

Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of the nitric oxide (NO)-synthase and a biomarker of endothelial dysfunction (ED). ED plays an important role in the pathogenesis of contrast-induced nephropathy (CIN). The aim of our study was to evaluate serum ADMA concentration as a bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Heunisch, Fabian, Chaykovska, Lyubov, von Einem, Gina, Alter, Markus, Dschietzig, Thomas, Kretschmer, Axel, Kellner, Karl-Heinz, Hocher, Berthold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313016/
https://www.ncbi.nlm.nih.gov/pubmed/28178159
http://dx.doi.org/10.1097/MD.0000000000006065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313016/
https://www.ncbi.nlm.nih.gov/pubmed/28178159
http://dx.doi.org/10.1097/MD.0000000000006065

Ejemplares similares